- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06106295
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
Metyrapone Intervention in Patients With Mild Autonomous Cortisol Secretion (MACS)
Study Overview
Status
Intervention / Treatment
Detailed Description
This study will look at how well metyrapone controls blood pressure, blood glucose, blood lipids and weight.
Metyrapone is approved in the United States of America (USA) by the Federal Drug Administration (FDA) for use in the diagnosis of adrenal insufficiency. It is not approved in the USA for the treatment of MACS. It is approved in Europe for the treatment of ACTH dependent Cushing's Syndrome.
Metyrapone is currently being tested to evaluate the safety (side effects/risks) and efficacy (benefits), so its use for the treatment of MACS is experimental in the USA. Its effectiveness is unproven in the USA and metyrapone is considered an investigational study drug in the USA. The Mayo Clinic IRB has given approval for this drug to be used in this setting.
Patients diagnosed with MACS have abnormal cortisol levels above the normal range. Cortisol acts by binding with the cortisol receptors in many tissues of the body. Metyrapone works by reducing cortisol production, thereby decreasing the effects of too much cortisol. Metyrapone doesn't affect levels of other hormones in your body.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Minnesota
-
Contact:
- Vanessa Fell
- Phone Number: 507-266-6068
- Email: fell.vanessa@mayo.edu
-
Principal Investigator:
- Irina Bancos, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provide written informed consent.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Diagnosed with MACS: at least 2 abnormal post-dexamethasone cortisol results (1 mg post-dexamethasone cortisol > 1.8 mcg/d; or 8 mg post-dexamethasone cortisol > 1 mcg/dL) and historical dexamethasone suppression test results can be used if performed within 24 months prior to enrollment.
- Adrenal imaging phenotype consistent with benign disease (adrenal adenoma/s, macronodular or micronodular adrenal hyperplasia).
- At least one of the following comorbidities: obesity (BMI > 30 kg/m^2); dysglycemia; dyslipidemia; hypertension; osteopenia; osteoporosis; fragility fractures.
- Ability to take oral medication and be willing to adhere to the study intervention regimen.
- For females of reproductive potential: use of highly effective contraception initiated prior to baseline visit and for 1 month after completing metyrapone study.
- For persons of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of <5% per year during the treatment period and for 6 months after the last dose of study treatment.
- Stable timing for bedtime for at least one week prior to on-site study visits
Exclusion Criteria:
- Planned alternative therapy for MACS within 6 months after joining the study.
- Current use of oral exogenous glucocorticoid therapy.
- Current use of opioid therapy > 20 MME/day.
- Planned use of oral exogenous glucocorticoid therapy.
- Planned use of opioid therapy > 20 MME/day.
- Use of injectable glucocorticoid within the last 6 weeks.
- Investigator's judgement based on history/physical examination that a comorbidity or concomitant medication may impact the hypothalamic-pituitary-adrenal axis or steroid metabolome.
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnancy or lactation.
- Known allergic reactions to metyrapone.
- Suspected false positive post-dexamethasone cortisol results due to increased metabolism, poor absorption, or noncompliance with dexamethasone.
- Treatment with another investigational drug or other intervention within lower than specific therapy washout period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mild Autonomous Cortisol Secretion (MACS) Open Label Phase and Optional Extension Phase
Subjects diagnosed with Mild Autonomous Cortisol Secretion (MACS) will receive metyrapone for a 6 month treatment period (Open Label Phase) with the option to continue for an additional 30 months of metyrapone therapy.
If a patient chooses to participate in the Optional Extension Phase they will continue to receive metyrapone therapy until Month 36.
This is an additional 30 months of therapy after completion of the Open Label Phase.
|
250 to 1000 milligram (mg) orally in one or two doses in the evening (administered 4 and 2 hours prior to bed)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 50 months
|
Number of participants to experience adverse events
|
50 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Irina Bancos, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-008085
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autonomous Cortisol Secretion
-
Chongqing Medical UniversityNot yet recruitingTreatment | Diagnosis | Adrenogenic Autonomic Cortisol Secretion
-
The Cleveland ClinicRecordati Rare DiseasesNot yet recruitingMild Autonomous Cortisol Secretion (MACS)United States
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingAdrenal Incidentaloma | Autonomous Cortisol Secretion | Non-functioning Adrenal AdenomasChina
-
Sparrow PharmaceuticalsRecruitingAutonomous Cortisol Secretion (ACS) | ACTH-Independent Cushing Syndrome | ACTH-Independent Adrenal Cushing Syndrome, SomaticUnited States, United Kingdom, France, Romania
-
Icahn School of Medicine at Mount SinaiAbbVieRecruitingMild Autonomous Cortisol ExcessUnited States
-
Sparrow PharmaceuticalsActive, not recruitingCortisol; Hypersecretion | Cortisol Overproduction | Cushing's Syndrome I | Cushing Disease Due to Increased ACTH Secretion | Cortisol Excess | Ectopic ACTH SecretionUnited States, Bulgaria, Romania
-
Benedictine UniversityUnknown
-
Gérond'ifRecruitingAutonomous Subjects, Aged 65 and Afraid of FallingFrance
-
BDH-Klinik Hessisch OldendorfActive, not recruitingAutonomous Sensory Meridian Response | AudiobookGermany
Clinical Trials on Metyrapone
-
HRA PharmaCompletedCushing's SyndromeGermany, Belgium, Italy, Hungary, Poland, Romania, Spain, Turkey
-
Istituto Auxologico ItalianoHRA PharmaRecruiting
-
Jane BarnesNational Institute for Health Research, United KingdomCompleted
-
Baker Heart Research InstituteUnknownObesity | Metabolic Syndrome | Insulin ResistanceAustralia
-
National Center for Research Resources (NCRR)University of TexasUnknownBrain Injury | Craniocerebral TraumaUnited States
-
Nationwide Children's HospitalCompletedAdrenal Insufficiency | Prader Willi SyndromeUnited States
-
Universitätsklinikum Hamburg-EppendorfCompleted
-
GlaxoSmithKlineCompletedDepressive Disorder and Anxiety DisordersUnited Kingdom
-
Eleonora SeeligCompletedGlucocorticoid EffectSwitzerland
-
Rose Research Center, LLCFoundation for a Smoke-Free World; Embera NeuroTherapeutics, Inc.RecruitingSmoking Cessation | Tobacco Use DisorderUnited States